On this page
Health economics and outcomes research is a systematic discipline that measures the clinical effectiveness, costs, and real-world impact of medical interventions. It answers concrete questions about whether treatments work, what they cost, and how patients actually use them in practice, informing decisions by payers, regulators, and clinicians.
- HEOR measures three distinct dimensions: whether a treatment achieves its clinical goals, what it costs relative to alternatives, and how it performs outside controlled trial settings.
- HEOR uses multiple study designs, randomized trials, observational studies, and economic models, each suited to different questions and constraints.
- HEOR findings directly shape payer coverage decisions, drug pricing negotiations, and the clinical guidelines that hospitals and physicians follow.
- HEOR conclusions depend heavily on modeling assumptions and data sources; the same underlying evidence can support different cost-effectiveness conclusions depending on discount rates and perspective.
- HEOR cannot predict individual patient outcomes or account for all real-world variation, and findings from controlled studies often diverge from actual clinical practice patterns.
Health economics and outcomes research, or HEOR, is the systematic measurement of how medical interventions perform in terms of clinical results, financial cost, and patient experience. It answers questions that neither pure clinical research nor accounting can answer alone: Does this drug work better than the alternative? What does that improvement cost? Will patients actually take it as prescribed? The answers shape whether insurers will pay for a treatment, how much manufacturers can charge, and which therapies clinicians recommend.
The field has grown substantially over the past 20 years, driven by pressure from payers to justify treatment costs and from regulators to understand real-world impact. HEOR is not a single method but a toolkit, combining clinical trial data, insurance claims, patient surveys, and economic models to build a picture of how interventions perform in practice. Understanding HEOR matters because its conclusions appear in the coverage decisions that determine whether you or your insurer will pay for a treatment, and because its limitations are real and often invisible to readers who encounter only the headline.
What health economics and outcomes research actually is
HEOR is the discipline that measures whether a medical intervention works, what it costs, and how it performs in real-world settings. It sits at the intersection of clinical evidence, financial analysis, and patient experience. Where a clinical trial answers "Does this drug reduce symptoms compared to placebo?", HEOR asks "Does it reduce symptoms better than the current standard treatment, and is that improvement worth the cost? Will patients stick with it? What happens when doctors use it outside the trial setting?"
The core insight of HEOR is that a treatment can be clinically effective and still fail in practice, because it costs too much, because patients do not tolerate it, because it does not work the same way in diverse real-world populations, or because simpler alternatives are nearly as good. HEOR provides the evidence to make that trade-off visible and quantifiable. Payers use HEOR to decide which drugs to cover. Manufacturers use HEOR to justify pricing. Clinicians use HEOR findings to choose between competing treatments. Regulators use HEOR to understand whether a new therapy actually improves healthcare in the populations that will receive it.
The three pillars HEOR measures
HEOR evaluates medical interventions across three distinct dimensions. Each answers a different question, and each requires different data and methods. Together, they create a complete picture of how a treatment performs.
Clinical effectiveness
Clinical effectiveness in HEOR means measuring whether a treatment achieves its intended health outcomes and for which patients. This is not the same as efficacy, which is what a controlled trial measures. Efficacy answers "Does this drug work under ideal conditions with carefully selected patients?" Effectiveness answers "Does it work in the patients who will actually receive it, with their comorbidities and concurrent medications, in real clinical practice?"
HEOR researchers measure effectiveness through multiple lenses. They may look at whether a drug reduces disease symptoms, extends survival, prevents complications, or improves function. They measure not just whether the outcome occurs, but how much it improves compared to alternatives. They also ask whether the benefit differs across subgroups, age, sex, disease severity, concurrent conditions. A drug that works well in younger patients with early-stage disease may perform differently in older patients or those with advanced illness. HEOR makes those differences explicit so decisions can account for them.
Economic cost and value
Economic cost and value in HEOR means quantifying what a treatment costs and comparing that cost to the health benefit it delivers. This is where HEOR moves beyond clinical measurement into financial analysis. The question is not "What does this drug cost?" but "What does it cost relative to the improvement in health it produces?"
Cost in HEOR includes direct medical costs, the price of the drug, the cost of administering it, the cost of monitoring for side effects, and sometimes indirect costs like lost work productivity. When assigning costs to health services, cost-effectiveness analysts typically use reimbursements as a proxy for opportunity cost, meaning they use what payers actually paid rather than list prices or manufacturing costs. Value is measured as cost per unit of health improvement, cost per year of life gained, cost per quality-adjusted life year, cost per case prevented. A treatment that costs twice as much as an alternative but produces three times the benefit may represent better value. A treatment that costs slightly less but produces much less benefit may not. HEOR makes that comparison explicit and quantifiable.
Real-world patient outcomes
Real-world patient outcomes in HEOR means measuring how treatments actually perform outside the controlled environment of a clinical trial. This includes quality of life, symptom burden, functional ability, and adherence, whether patients actually take the medication as prescribed. It also includes outcomes that matter to patients but may not appear in trials: ability to work, ability to care for family, social participation, satisfaction with treatment.
Real-world outcomes differ from trial outcomes because trial populations are selected, monitored intensively, and receive treatments under controlled conditions. Patients in practice are diverse, often forget doses, sometimes stop treatment because of side effects or cost, and receive care in settings with varying quality. A drug that works well when patients take it consistently may perform poorly when adherence is lower. A drug that is tolerable in a short trial may cause side effects that accumulate over years of use. HEOR captures these real-world patterns by drawing data from insurance claims, electronic health records, patient registries, and surveys. The result is evidence about how treatments actually perform in the populations and settings where they will be used.
How HEOR research is conducted
HEOR researchers employ multiple study designs and data sources, each suited to different research questions and constraints. The goal is to build evidence that is both rigorous and relevant to real-world decision-making.
Study designs HEOR employs
HEOR uses three main study designs, often in combination. Randomized controlled trials, the gold standard in clinical research, assign patients randomly to treatment or control and measure outcomes under standardized conditions. Trials produce the strongest evidence for whether a treatment works, but they are expensive, slow, and enroll selected populations that may not represent real-world patients. HEOR researchers use trials when the question is whether a treatment has an effect, but trials alone cannot answer whether that effect translates to better outcomes in practice.
Observational studies follow patients who have chosen or been assigned to different treatments and measure outcomes as they occur in real practice. These studies are faster and cheaper than trials, and they include diverse patients and real-world settings. The trade-off is that patients who receive different treatments may differ in ways that affect outcomes, sicker patients may receive more aggressive treatment, or healthier patients may be more likely to tolerate side effects. HEOR researchers use statistical methods to adjust for these differences, but the adjustment is imperfect. Observational studies are essential for understanding real-world effectiveness, but they cannot prove causation the way trials can.
Economic models combine data from trials, observational studies, and other sources to project costs and outcomes over time or across populations. A model might use trial data showing that a drug reduces disease progression, insurance claims data showing the cost of treatment, and registry data showing how long patients survive. The model then projects lifetime costs and health outcomes, answering questions that no single study can answer. Models are powerful tools for decision-making, but their conclusions depend on assumptions about how the future will unfold and how different data sources fit together.
Data sources HEOR draws from
HEOR researchers draw data from multiple sources, each with strengths and limitations. Insurance claims databases contain records of medical services, prescriptions, and costs for millions of patients over years. These databases are large, representative of insured populations, and include real-world treatment patterns and outcomes. The limitation is that claims data capture only what was billed, they do not include clinical details like disease severity, laboratory values, or reasons for treatment decisions.
Electronic health records contain detailed clinical information, diagnoses, test results, medications, provider notes, but typically cover smaller populations and shorter time periods than claims databases. Patient registries are databases where patients with a specific disease or condition enroll and report outcomes, often including quality of life and functional measures that claims data do not capture. Patient surveys ask people directly about their health, treatment experience, and outcomes. Each data source answers different questions and has different limitations. HEOR studies often combine multiple sources to build a more complete picture. Harvard Pilgrim Health Care Inc., for example, contracted with Illumina, Inc. to evaluate non-invasive prenatal testing by assessing costs and outcomes for low- and average-risk pregnancies, drawing on claims data to understand costs and clinical outcomes to understand effectiveness.
Why HEOR shapes healthcare decisions
HEOR findings directly inform three types of decisions that determine patient access to treatments and how healthcare dollars are spent. HEOR provides insights that inform decision-making on healthcare policies, clinical guidelines, and resource allocation.
Payer coverage decisions are the most direct application. Insurers and government programs use HEOR evidence to decide whether to cover a treatment and under what conditions. A payer might cover a new drug only for patients with advanced disease, or only if it is used in combination with another treatment, or only after a cheaper alternative has been tried. These decisions are made using HEOR evidence about effectiveness and cost-effectiveness. Concordance between private payer coverage decisions and Medicare coverage decisions is estimated at approximately 50%, with roughly 25% of private payer decisions being more generous than Medicare and another 25% being less generous. This variation reflects different interpretations of HEOR evidence and different priorities across payers.
Drug pricing and reimbursement negotiations use HEOR evidence to justify prices. Manufacturers present HEOR analyses showing that a new drug is more effective than existing alternatives or that its cost per unit of benefit is reasonable. Payers use HEOR evidence to negotiate prices, if HEOR shows that a drug is only marginally better than a cheaper alternative, payers will negotiate harder on price. Clinical guidelines use HEOR evidence to recommend which treatments to use first, which to reserve for patients who do not respond to first-line therapy, and which combinations to use. These guidelines shape how clinicians practice and which treatments patients receive.
Common limitations and misreadings of HEOR
HEOR produces rigorous evidence, but that evidence has real limitations that are often invisible to readers who see only the conclusions. Understanding these limitations is essential for reading HEOR studies critically.
The gap between trials and real-world practice
Clinical trials measure outcomes under controlled conditions with selected patients who are monitored intensively. Real-world practice is messier. Patients are more diverse, have more concurrent conditions, take more concurrent medications, and receive care in settings with varying quality and resources. Adherence is lower. Dosing is often adjusted based on individual response. Patients switch treatments or stop treatment. The result is that a treatment's real-world effectiveness often differs from its trial efficacy, sometimes better, sometimes worse.
HEOR researchers try to bridge this gap by measuring real-world effectiveness directly through observational studies and claims data. But observational data has its own limitations. Patients who receive different treatments differ in ways that affect outcomes, and statistical adjustment cannot fully account for those differences. A drug that appears less effective in observational data might actually be less effective in practice, or it might be prescribed to sicker patients who would have worse outcomes regardless. HEOR researchers use methods to address this problem, but the uncertainty remains. The implication is that a HEOR study showing that a drug works well in trials may not predict how well it will work in your practice or your population.
How assumptions shape cost-effectiveness conclusions
Economic models project costs and outcomes into the future and across populations. These projections require assumptions about how long patients will live, how disease will progress, how treatment effects will persist, what future treatments will cost, and how to value future health compared to present health. Small changes in these assumptions can produce large changes in conclusions.
Suppose a model projects lifetime costs and outcomes for a new cancer drug. The model assumes patients will live five years longer with the drug than without it. If that assumption is wrong and patients actually live three years longer, the cost per year of life gained increases substantially, potentially changing whether the drug is considered cost-effective. The model also assumes a discount rate, a factor that reduces the value of future health and costs to reflect time preference. A higher discount rate makes future benefits worth less, making the drug appear less cost-effective. A lower discount rate makes future benefits worth more, making the drug appear more cost-effective. The choice of discount rate is not arbitrary, but it is a choice, and different choices produce different conclusions from the same underlying data.
The implication is that HEOR conclusions about cost-effectiveness are not purely empirical facts. They depend on modeling choices that are somewhat subjective. Two analysts looking at the same data can reach different conclusions about whether a treatment is cost-effective. This does not mean HEOR is unreliable, the analyses are rigorous and transparent, but it means HEOR conclusions should be read as informed estimates rather than objective facts.
How HEOR connects to adjacent research disciplines
HEOR sits within a broader landscape of research disciplines that inform healthcare decisions. Understanding these adjacent fields helps clarify what HEOR does and does not do.
Clinical epidemiology measures disease frequency and outcomes in populations, answering questions about who gets sick and why. HEOR draws on epidemiological data but adds economic and patient-centered dimensions. Comparative effectiveness research measures how different treatments perform relative to each other in real-world settings. HEOR includes comparative effectiveness research but extends it to include cost and patient outcomes. Health services research studies how healthcare systems work and how to improve them. HEOR is a component of health services research focused specifically on measuring intervention outcomes and costs. Pharmacoeconomics is sometimes used as a synonym for HEOR, though it originally referred more narrowly to the economics of pharmaceutical treatments. Real-world evidence research uses data from actual clinical practice rather than trials. HEOR uses real-world evidence but also uses trial data and models. Patient-reported outcomes research measures outcomes that patients report directly. HEOR includes patient-reported outcomes as one component of a broader measurement framework.
These disciplines overlap and inform each other. A HEOR study might use methods from clinical epidemiology to measure disease frequency, comparative effectiveness research to compare treatments, health services research to understand implementation, and patient-reported outcomes research to measure quality of life. The result is evidence that is both clinically rigorous and relevant to real-world decision-making. Both technical and soft skills are necessary for professionals to be capable of improving healthcare decision-making, and HEOR competencies are organized into different domains to highlight areas for career growth while pointing professionals toward development opportunities for the future.
Do this automatically
Manually compiling clinical effectiveness data, economic costs, and real-world patient outcomes across multiple study designs and data sources requires researchers to spend weeks or months organizing, cross-referencing, and synthesizing information that spans trials, registries, and patient records. Software can automate the collection, standardization, and integration of these three HEOR pillars from disparate sources, reducing the time required to move from raw data to actionable analysis. Healthcare research runs this kind of analysis end to end and cites every figure back to its original source, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
